Trigemina Stock
Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.
Sign up today and learn more about Trigemina Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Trigemina Stock
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
Funding History
| December 2006 | $2.0M |
|---|---|
| December 2009 | $305K |
| October 2010 | $400K |
| April 2014 | $8.0M |
| June 2015 | $10.0M |
| July 2017 | $2.4M |
Management
Chief Medical Officer
Shashidhar Kori
Co-Founder
Martin Angst
Co-Founder
William Frey II
Chief Medical Advisor
Stephen Silberstein
Founder, Chief Scientist
David C Yeomans
Chairman
Charles Yeomans
Chief Financial Officer & Chief Operating Officer
Michael Leonard
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
